In the Claims

Please amend the claims according to the claim listing provided below.

1. (original) A compound of Formula (I):



(I)

wherein:

W and Y are independently a straight or branched chain C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

X is $-NR_3C(O)-$, $-C(O)NR_3$, $-NR_3S(O)_2-$, $-S(O)_2NR_3-$, $-NR_3C(O)NR_4-$, $-NR_3C(O)O-$, $-OC(O)NR_3-$, $-NR_3-$, -C(O)-, -CH(OH)-, -C(NH)-, -O-, -S-, -S(O)- or $-S(O)_2-$;

R_3 and R_4 are independently H, C_{1-4} alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

R_1 is H, hydroxyl, halogen, C_{1-4} alkyl or C_{1-4} haloalkyl;

R_2 is H or C_{1-8} alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that:

i) when both R_1 and R_2 are H then $-[W]_n-X-[Y]_m-Z$ together is not CO_2H, $C(O)-C_6H_4-p-O-C_8H_{17}$, OCH_2CH_3, OH, $CH_2CH_2CH_2CH_2CO_2H$, $CH_2CH_2CH_2CO_2H$, CH_2CO_2H and $CH_2CH_2CO_2H$;

ii) when R_1 is CH_3 and R_2 is H then $-[W]_n-X-[Y]_m-Z$ together is not CH_2CO_2H, $C(O)CH{=}CH\ C_6H_5$, $C(O)C_6H_4-p-OCH_3$, CO_2H, $C(O)CH_3$, $C(O)C_6H_4-o-CH_3$, $C(O)C_6H_4-o-Br$, $C(O)C_6H_4-o-Cl$, and $C(O)C_6H_5$;

iii) when R_1 is Br and R_2 is H then $-[W]_n-X-[Y]_m-Z$ together is not CO_2H;

iv) when R_1 is OH and R_2 is H then $-[W]_n-X-[Y]_m-Z$ together is not CO_2H;

v) when R_1 is H and R_2 is CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not 2,6-dichloro-4-trifluoromethylphenoxy, $C(O)NH-C_6H_4-p-OCH_2CH_3$, $NHC(O)CH(CH_3)_2$, SCH_3, $C(O)-C_6H_4-p-O-C_8H_{17}$, SCH_2CH_3, $C(O)NHC_6H_5$, $CH(OCH_3)_2$, $CH_2OC(O)CH_3$, CO_2H, CO_2CH_3, $C(O)C_6H_4-p-NO_2$, $C(O)C_6H_5$, $CH_2CH_2CO_2CH_3$, $CH_2CH_2CH_2CH_2CO_2CH_3$, $CH_2CH_2CH_2CO_2CH_3$ and $CH_2CO_2CH_3$;

vi) when R_1 is OH and R_2 is CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH_2OCH_2C_6H_5$, $CH_2OCH(CH_3)_2$ and CH_2OH;

vii) when R_2 is CH_3 then:

R_1 is not CH_3 and $-[W]_n-X-[Y]_m-Z$ together is not 2,6-dichloro-4-trifluoromethylphenoxy;

R_1 is not I and $-[W]_n-X-[Y]_m-Z$ together is not $CO_2C(CH_3)_3$;

R_1 is not $C(CH_3)_3$ and $-[W]_n-X-[Y]_m-Z$ together is not formyl;

R_1 is not Br and $-[W]_n-X-[Y]_m-Z$ together is not CO_2CH_3;

and

R_1 is not $CH_2CH_2CH_2CH_3$ and $-[W]_n-X-[Y]_m-Z$ together is not formyl;

viii) when R_1 is H and R_2 is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH_2SCH_2CH_3$, $OCH_2CH_2CH{=}CH_2$, $CH_2CH_2CH_2OH$, CH_2CH_2CHO, $CO_2CH_2CH_3$, OCH_3, $C(O)CH_2Br$, $CO_2C_8H_{17}$, formyl, OH, $CH_2N(CH_2CH_2Cl)_2$, $CH(CH_3)OC(O)CH_3$, CH_2OH, $CH_2OC(O)CH_3$, $C(O)CH_3$, $C(O)C_6H_5$ and $C(O)NHCH_2CO_2CH_2CH_3$.

ix) when R_1 is CH_3 and R_2 is CH_2CH_3 then $-[W]_n-X-[Y]_m-Z$ together is not $CH(OH)C_6H_4-p-N(CH_3)_2$, $C(O)CH_2C(O)CH_3$, $CO_2CH_2C_6H_5$, CO_2CH_3, $C(O)CH_2CH_2CH_3$,

$C(O)CH_3$, $C(O)C_6H_4$-*p*-OCH_3, $C(O)C_6H_4$-*o*-Br, $C(O)C_6H_4$-*p*-Cl, $C(O)C_6H_4$-*o*-Cl, $C(O)CH_2C_6H_5$ and $C(O)C_6H_5$;

x) when R_2 is CH_2CH_3 then:

R_1 is not I and $-[W]_n$-X-$[Y]_m$-Z together is not $CO_2CH_2CH_3$;

R_1 is not CF_3 and $-[W]_n$-X-$[Y]_m$-Z together is not $CO_2CH_2CH_3$;

and

R_1 is not Br and $-[W]_n$-X-$[Y]_m$-Z together is not $CO_2CH_2CH_3$;

xi) when R_1 is OH and R_2 is CH_2CH_3 then $-[W]_n$-X-$[Y]_m$-Z together is not $C(O)C_6H_5$, $C(O)NH_2$ and $CO_2CH_2CH_3$;

xii) when R_1 is H and R_2 is $C(CH_3)_3$ then $-[W]_n$-X-$[Y]_m$-Z together is not $CO_2C(CH_3)_3$, $C(O)NHC(O)CH_3$ and $C(O)NH_2$;

xiii) when R_1 is OH and R_2 is $CH_2CH_2CH_2CH_3$ then $-[W]_n$-X-$[Y]_m$-Z together is not $C(O)C_6H_5$; and

xiv) when X is $-NR_3$- then "n" is 1.

2. (original) The compound according to claim 1 wherein "n" is 0.

3. (original) The compound according to claim 1 wherein "n" is 1.

Claims 4 to 149 deleted.

150. (new) The compound according to claim 1 wherein "m" is 0.

151. (new) The compound according to claim 1 wherein "m" is 1.

152. (new) The compound according to claim 1 wherein W is the straight or branched C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

153. (new) The compound according to claim 152 wherein W is selected from the group consisting of $-CH_2$-, $-CH_2CH_2$-, $-CH(CH_3)CH_2$-, $-CH_2CH(CH_3)$-,

$-C(CH_3)_2CH_2-$, $-CH_2C(CH_3)_2-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-CH_2C(O)-$, $-C(O)CH_2-$, $-CH(CH_3)C(O)-$, $-C(O)CH(CH_3)-$, $-CH_2CH_2C(O)-$, $-C(O)CH_2CH_2-$, $-C(CH_3)_2C(O)-$, $-C(O)C(CH_3)_2-$, $-C(CH_3)_2CH_2C(O)-$, $-C(O)CH_2C(CH_3)_2-$, $-CH_2C(O)CH_2-$, $-CH_2CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH_2-$, $-CH(CH_3)CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH(CH_3)-$, $-CH_2CH_2C(O)CH_2-$, $-CH_2C(O)CH_2CH_2-$, $-CH=CHC(O)-$, $-C(O)CH=CH-$, $-C(CH_3)=CHC(O)-$, and $-C(O)CH=C(CH_3)-$, each optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

154. (new) The compound according to claim 152 wherein W is $-CH(CH_3)-$, $-CH(OCH_3)CH_2-$, or $-CH_2CH(OCH_3)-$, each optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

155. (new) The compound according to claim 152 wherein W is selected from the group consisting of $-CH_2-$, $-CH(CH_3)-$, $-C(CH_3)_2-$, $-CH_2CH_2-$, $-CH(CH_3)CH_2-$, $-CH_2CH(CH_3)-$, $-C(CH_3)_2CH_2-$, $-CH_2C(CH_3)_2-$, $-CH(OCH_3)CH_2-$, $-CH_2CH(OCH_3)-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-CH_2C(O)-$, $-C(O)CH_2-$, $-CH(CH_3)C(O)-$, $-C(O)CH(CH_3)-$, $-CH_2CH_2C(O)-$, $-C(O)CH_2CH_2-$, $-C(CH_3)_2C(O)-$, $-C(O)C(CH_3)_2-$, $-C(CH_3)_2CH_2C(O)-$, $-C(O)CH_2C(CH_3)_2-$, $-CH_2C(O)CH_2-$, $-CH_2CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH_2-$, $-CH(CH_3)CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH(CH_3)-$, $-CH_2CH_2C(O)CH_2-$, $-CH_2C(O)CH_2CH_2-$, $-CH=CHC(O)-$, $-C(O)CH=CH-$, $-C(CH_3)=CHC(O)-$, and $-C(O)CH=C(CH_3)-$.

156. (new) The compound according to claim 152 wherein W is $-CH=CH-$, $-C\equiv C-$, or $-C(O)-$.

157. (new) The compound according to claim 1 wherein Y is the straight or branched chain C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

158. (new) The compound according to claim 157 wherein Y is selected from the group consisting of $-CH_2-$, $-CH_2CH_2-$, $-CH(CH_3)CH_2-$, $-CH_2CH(CH_3)-$,$-C(CH_3)_2CH_2-$, $-CH_2C(CH_3)_2-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-C\equiv CCH_2-$, $-CH_2C\equiv C-$, $-CH_2C(O)-$, $-C(O)CH_2-$, $-CH(CH_3)C(O)-$, $-C(O)CH(CH_3)-$, $-CH_2CH_2C(O)-$, $-C(O)CH_2CH_2-$,

$-C(CH_3)_2CH_2C(O)-$, $-C(O)CH_2C(CH_3)_2-$, $-CH_2C(O)CH_2-$, $-CH_2CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH_2-$, $-CH(CH_3)CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH(CH_3)-$, $-CH_2CH_2C(O)CH_2-$, $-CH_2C(O)CH_2CH_2-$, $-CH=CHC(O)-$, $-C(O)CH=CH-$, $-C(CH_3)=CHC(O)-$, and $-C(O)CH=C(CH_3)-$, each optionally substituted with halogen, hydroxyl, C_{1-4} alkyl or C_{1-4} alkoxy.

159. (new) The compound according to claim 157 wherein Y is selected from the group consisting of $-CH_2-$, $-CH_2CH_2-$, $-CH(CH_3)CH_2-$, $-CH_2CH(CH_3)-$,$-C(CH_3)_2CH_2-$, $-CH_2C(CH_3)_2-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-C\equiv CCH_2-$, $-CH_2C\equiv C-$, $-CH_2C(O)-$, $-C(O)CH_2-$, $-CH(CH_3)C(O)-$, $-C(O)CH(CH_3)-$, $-CH_2CH_2C(O)-$, $-C(O)CH_2CH_2-$, $-C(CH_3)_2CH_2C(O)-$, $-C(O)CH_2C(CH_3)_2-$, $-CH_2C(O)CH_2-$, $-CH_2CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH_2-$, $-CH(CH_3)CH_2CH_2C(O)-$, $-C(O)CH_2CH_2CH(CH_3)-$, $-CH_2CH_2C(O)CH_2-$, $-CH_2C(O)CH_2CH_2-$, $-CH=CHC(O)-$, $-C(O)CH=CH-$, $-C(CH_3)=CHC(O)-$, and $-C(O)CH=C(CH_3)-$.

160. (new) The compound according to claim 157 wherein Y is $-CH(CH_3)-$ optionally substituted with halogen, hydroxyl or C_{1-4} alkoxy.

161. (new) The compound according to claim 157 wherein Y is $-CH(OCH_3)CH_2-$ or $-CH_2CH(OCH_3)-$ optionally substituted with halogen, hydroxyl or C_{1-4} alkyl.

162. (new) The compound according to claim 157 wherein Y is $-CH=CH-$ optionally substituted with C_{1-4} alkyl or C_{1-4} alkoxy.

163. (new) The compound according to claim 157 wherein Y is $-C(CH_3)_2-$, $-C\equiv C-$, $-C(O)-$, $-C(CH_3)_2C(O)-$, or $-C(O)C(CH_3)_2-$.

164. (new) The compound according to claim 1 wherein X is $-NHC(O)-$ or $-C(O)NH-$.

165. (new) The compound according to claim 1 wherein X is $-NH-$ or $-NCH_3-$.

166. (new) The compound according to claim 1 wherein X is selected from the group consisting of $-C(O)-$, $-CH(OH)-$, $-C(NH)-$, $-O-$, $-S-$, $-S(O)-$, or $-S(O)_2-$.

167. (new) The compound according to claim 1 wherein Z is H, halogen, or phenyl.

168. (new) The compound according to claim 1 wherein Z is phenyl optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, $-CF_3$, $-NHCH_3$, $-N(CH_3)_2$, $-CH_3$, $-CH_2CH_3$, $-OCH_3$ and $-OCF_3$.

169. (new) The compound according to claim 1 wherein Z is heteroaryl optionally substituted with 1 to 3 substituents selected from the group consisting of -F, -Cl, -Br, $-CF_3$, $-NHCH_3$, $-N(CH_3)_2$, $-CH_3$, $-CH_2CH_3$, $-OCH_3$ and $-OCF_3$.

170. (new) The compound according to claim 1 wherein R_1 is H.

171. (new) The compound according to claim 1 wherein R_1 is hydroxyl.

172. (new) The compound according to claim 1 wherein R_1 is halogen.

173. (new) The compound according to claim 1 wherein R_1 is C_{1-4} alkyl.

174. (new) The compound according to claim 1 wherein R_1 is C_{1-4} haloalkyl.

175. (new) The compound according to claim 1 wherein R_2 is H.

176. (new) The compound according to claim 1 wherein R_2 is C_{1-8} alkyl.

177. (new) The compound according to claim 1 selected from the group consisting of:
5-Ethylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;
5-Ethanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;
5-Ethanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;
5-(2-Oxo-propoxymethyl)-1H-pyrazole-3-carboxylic acid;
5-Prop-2-ynyloxymethyl-1H-pyrazole-3-carboxylic acid;
5-Carbamoyl-1H-pyrazole-3-carboxylic acid;
5-(1-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1,1-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Carboxy-1,1-dimethyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Acetoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Chloro-3-hydroxy-propyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Carboxy-1-methyl-vinyl)-1H-pyrazole-3-carboxylic acid;

5-Propylcarbamoylmethyl-1H-pyrazole-3-carboxylic acid;

5-(2-Amino-vinyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Amino-propyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Dimethylamino-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Hydroxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Hydroxy-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid

5-(2-Hydroxy-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Carboxy-1-methyl-propyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Carboxy-vinyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Methoxy-vinyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Acetoxy-propyl)-1H-pyrazole-3-carboxylic acid;

5-Carbamoylmethyl-1H-pyrazole-3-carboxylic acid;

5-Hydroxymethyl-1H-pyrazole-3-carboxylic acid;

5-(2,2-Dimethoxy-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Imino-propyl)-1H-pyrazole-3-carboxylic acid;

5-(2-Amino-2-methyl-propyl)-1H-pyrazole-3-carboxylic acid;

5-(Ethoxycarbonyl-fluoro-methyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-Ethoxycarbonylmethyl-1H-pyrazole-3-carboxylic acid;

5-(2-Ethoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;

5-(1-Methoxycarbonyl-1-methyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(1-Hydroxy-1-methoxycarbonyl-ethyl)-1H-pyrazole-3-carboxylic acid;

5-(3-Methoxycarbonyl-propyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Methoxycarbonyl-vinyl)-1H-pyrazole-3-carboxylic acid;
5-Dimethylcarbamoylmethyl-1H-pyrazole-3-carboxylic acid;
1H-Pyrazole-3,5-dicarboxylic acid;
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid;
5-(2-Methoxy-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methoxy-propyl)-1H-pyrazole-3-carboxylic acid;
5-Methylsulfanylmethyl-1H-pyrazole-3-carboxylic acid;
5-Methanesulfinylmethyl-1H-pyrazole-3-carboxylic acid;
5-Methanesulfonylmethyl-1H-pyrazole-3-carboxylic acid;
5-(2-Methylsulfanyl-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Methanesulfinyl-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Methanesulfonyl-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methylsulfanyl-propyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methanesulfinyl-propyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Methanesulfonyl-propyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Amino-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Methylamino-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Dimethylamino-ethyl)-1H-pyrazole-3-carboxylic acid;
5-(2-Oxo-propyl)-1H-pyrazole-3-carboxylic acid;
5-(3-Oxo-butyl)-1H-pyrazole-3-carboxylic acid;
5-(Benzylamino-methyl)-1H-pyrazole-3-carboxylic acid;
5-Methoxymethyl-1H-pyrazole-3-carboxylic acid;
5-Ethoxymethyl-1H-pyrazole-3-carboxylic acid; and
5-(2,2-Diethoxy-ethyl)-1H-pyrazole-3-carboxylic acid; or
a pharmaceutically acceptable salt, solvate or hydrate thereof.

178. (new) A pharmaceutical composition comprising a pharmaceutically acceptable carrier in combination with at least one compound according to Formula (**I**):



(I)

wherein:

W and Y are independently a straight or branched chain C_{1-5} alkylene group optionally containing one double bond, one triple bond or carbonyl, wherein said C_{1-5} alkylene group is optionally substituted with halogen, hydroxyl, C_{1-4} alkyl, C_{1-4} haloalkyl or C_{1-4} alkoxy;

X is $-NR_3C(O)-$, $-C(O)NR_3$, $-NR_3S(O)_2-$, $-S(O)_2NR_3-$, $-NR_3C(O)NR_4-$, $-NR_3C(O)O-$, $-OC(O)NR_3-$, $-NR_3-$, -C(O)-, -CH(OH)-, - C(NH)-, - O-, -S-, -S(O)- or $-S(O)_2-$;

R_3 and R_4 are independently H, C_{1-4} alkyl, phenyl or heteroaryl, wherein each of said alkyl, phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxyl, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

Z is H, halogen, phenyl or heteroaryl, wherein said phenyl and heteroaryl are optionally substituted with 1 to 5 substituents selected from the group consisting of halogen, hydroxy, thiol, cyano, nitro, C_{1-4} haloalkyl, amino, C_{1-4} alkylamino, di-C_{1-4}-alkylamino, C_{1-4} alkyl, C_{1-4} alkoxy, C_{2-4} alkenyl, C_{2-4} alkynyl, C_{1-4} haloalkoxy, C_{1-4} alkylthio, C_{1-4} alkylsulfinyl, C_{1-4} alkylsulfonyl, C_{1-4} haloalkylthio, C_{1-4} haloalkylsulfinyl and C_{1-4} haloalkylsulfonyl;

R_1 is H, hydroxyl, halogen, C_{1-4} alkyl or C_{1-4} haloalkyl;

R_2 is H or C_{1-8} alkyl and

"n" and "m" are each independently 0 or 1; or

a pharmaceutically acceptable salt, solvate or hydrate thereof;

provided that when X is $-NR_3-$ then "n" is 1.

179. A method for prophylaxis or treatment of a metabolic-related disorder in an individual in need of said prophylaxis or treatment comprising administering to the individual a therapeutically effective amount of a compound according to claim 1 or a pharmaceutical composition according to claim 178.

180. The method according to claim 179 wherein the metabolic-related disorder is selected from the group consisting of dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, obesity, impaired glucose tolerance, atheromatous disease, hypertension, stroke, Syndrome X, heart disease and type 2 diabetes.

181. The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance and type 2 diabetes.

182. The method according to claim 180 wherein the metabolic-related disorder is dyslipidemia.

183. The method according to claim 180 wherein the metabolic-related disorder is atherosclerosis.

184. The method according to claim 180 wherein the metabolic-related disorder is coronary heart disease.

185. The method according to claim 180 wherein the metabolic-related disorder is insulin resistance.

186. The method according to claim 180 wherein the metabolic-related disorder is type 2 diabetes.

187. The method of producing a pharmaceutical composition comprising admixing at least one compound according to claim 1 and a pharmaceutically acceptable carrier or excipient.